Laura C. Seidman

ORCID: 0000-0003-1442-0981 · 6 papers in corpus
other 2026
Frontiers in pain research (Lausanne, Switzerland) ·doi:10.3389/fpain.2026.1878751

INTRODUCTION: Non-steroidal anti-inflammatory drugs (NSAIDs) are considered a first-line treatment for dysmenorrhea (menstrual pain). However, as much as 20% of women fail to achieve sufficient pain relief from NSAIDs, although factors asso…

article 2025
·doi:10.1016/j.jpag.2025.10.009

Study objectiveTo evaluate multi-site pain (i.e., number of painful body regions) during menstruation in a sample of adolescents, and to assess relationships between multi-site pain during menstruation and other menstrual cycle, pain, and p…

2025
Pain reports ·doi:10.1097/pr9.0000000000001315

IntroductionThe Menstrual Sensitivity Index (MSI), assessing the attunement to and fear of menstrual symptoms, was recently developed and validated in an adult sample.ObjectivesThe objective of this study was to validate the MSI in adolesce…

article 2021
Psychology, health & medicine ·doi:10.1080/13548506.2021.1948581

The aim of this study was to understand the relationship between psychosocial factors, including mental health, pain cognitions and social support associated with menstrual pain severity in women with dysmenorrhea of no identified medical c…

2020
Journal of pain research ·doi:10.2147/jpr.s283363

PurposePrimary dysmenorrhea (PD; menstrual pain without an identified organic cause) has been proposed as a possible risk factor for the development of chronic pelvic pain, but the mechanism through which this process occurs is unknown. One…

article 2020
Pain medicine (Malden, Mass.) ·doi:10.1093/pm/pnaa362

OBJECTIVE: Primary dysmenorrhea and secondary dysmenorrhea due to endometriosis share overlapping symptoms and likely demonstrate aspects of central sensitization. The present study aimed to identify distinct phenotypes of women who have dy…